Zelluna ASA (OSTO:ULTIO) Shares Outstanding (EOP): 26.27 Mil (As of Mar. 2026)


OSTO:ULTIO Zelluna ASA OSTO:ULTIO
28 GF Score
Price kr21.95
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA Shares Outstanding (EOP)?

Zelluna ASA OSTO:ULTIO 28 Shares Outstanding (EOP) is 26.27 Mil as of Mar. 2026. GuruFocus rates OSTO:ULTIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Zelluna ASA's shares outstanding for the quarter that ended in Mar. 2026 was 26.27 Mil.

Zelluna ASA's quarterly shares outstanding stayed the same from Dec. 2025 (26.27 Mil) to Mar. 2026 (26.27 Mil).

Zelluna ASA's annual shares outstanding increased from Dec. 2024 (3.44 Mil) to Dec. 2025 (26.27 Mil). It means Zelluna ASA issued new shares from Dec. 2024 to Dec. 2025 .


Zelluna ASA  (OSTO:ULTIo) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Zelluna ASA Shares Outstanding (EOP) Related Terms


Zelluna ASA Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA Shares Outstanding (EOP) Chart

Zelluna ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 3.44 3.44 3.44 26.27

Zelluna ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.23 20.45 20.45 26.27 26.27

OSTO:ULTIO vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Zelluna ASA's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelluna ASA Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelluna ASA's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Zelluna ASA's Shares Outstanding (EOP) falls into.


OSTO:ULTIO
28GF Score
Zelluna ASA OSTO:ULTIO
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 26.27 Mil mean?
Zelluna ASA (OSTO:ULTIO) has a Shares Outstanding (EOP) of 26.27 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Zelluna ASA and its competitors.
Is Zelluna ASA's Shares Outstanding (EOP) too high?
Zelluna ASA's current Shares Outstanding (EOP) is 26.27 Mil. Overall, Zelluna ASA has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's Shares Outstanding (EOP) compare to VRTX and REGN?
Zelluna ASA's Shares Outstanding (EOP) of 26.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Zelluna ASA and its competitors. Zelluna ASA's current Shares Outstanding (EOP) is 26.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (OSTO:ULTIO) has a current Shares Outstanding (EOP) of 26.27 Mil. The current Shares Outstanding (EOP) is 26.27 Mil. Zelluna ASA's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current Shares Outstanding (EOP) is 26.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway7UM0:Germany
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
28GF Score

Get the complete analysis for OSTO:ULTIO

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.95
Price